AstraZeneca invests in AI collaboration for cancer drug trials

AstraZeneca in AI collaboration with Immunai to inform cancer drug ...

AstraZeneca will pay $18 million to biotechnology firm Immunai Inc to use the New York-based firm's AI model of the immune system to make ...

Immunai and AstraZeneca's $18 Million AI Collaboration to ...

Immunai and AstraZeneca's $18 Million AI Collaboration to Transform Cancer Drug Development ... Immunai and AstraZeneca's $18 million AI ...

Israeli AI startup forges $18m partnership with AstraZeneca for ...

As part of the collaboration, drugmaker will use Immunai's AI model of the immune system and machine learning for clinical decision-making ...

AstraZeneca in AI Collaboration With Immunai to Inform Cancer ...

This is the latest in a string of tie-ups by Anglo-Swedish drugmaker AstraZeneca to use artificial intelligence for drug discovery and ...

AstraZeneca extends AI immuno-oncology R&D pact with Immunai

AstraZeneca is extending its work with Immunai through a multiyear collaboration that aims to implement its artificial-intelligence-powered immune cell atlas.

AstraZeneca Joins Forces With Immunai In $18 Million AI Deal

AstraZeneca invests in Immunai's AI technology to boost cancer drug trials. ... This collaboration underscores a broader trend of biotech companies harnessing AI ...

Owkin Announces Partnership with AstraZeneca to Develop an AI ...

Owkin Announces Partnership with AstraZeneca to Develop an AI gBRCA Pre-Screen Solution for Breast Cancer · Thomas Clozel, MD, CEO of Owkin, said ...

Immunai, AstraZeneca collaborate to optimize cancer clinical trials

Immunai Inc., a New York-based artificial intelligence and biotech company specializing in mapping the human immune system, has announced a ...

AstraZeneca launches Evinova, a health-tech business to accelerate ...

AstraZeneca launches Evinova, a health-tech business to accelerate innovation across the life sciences sector, the delivery of clinical trials ...

AstraZeneca invests in AI collaboration for cancer drug trials

AstraZeneca invests in AI collaboration for cancer drug trials. The British-Swedish pharmaceutical giant is partnering with biotechnology firm ...

Pioneering AI-powered solutions in emerging markets - AstraZeneca

Learn more about how we are harnessing artificial intelligence technology to improve health equity where the burden of non-communicable ...

AstraZeneca invests $18 million in Immunai's AI technology

This collaboration aligns with AstraZeneca's broader strategy to harness artificial AI for drug discovery and development, building on a ...

Immunai and AstraZeneca Collaborate to Optimize Oncology ...

Immunai, a New York-based AI biotech company, has entered a multi-year collaboration with AstraZeneca to optimize oncology clinical trials.

AstraZeneca announces collaboration and investment agreement ...

AstraZeneca continues to advance our ambition in cell therapy for oncology and autoimmune diseases as well as in genomic medicine, which has ...

AstraZeneca, Absci sign $247M agreement to uncover AI-driven ...

The companies will leverage Absci's AI-enabled Integrated Drug Creation platform and the pharma giant's oncology research and development ...

AstraZeneca starts artificial intelligence collaboration to accelerate ...

The future of drug discovery and development lies in bridging the gap between AI, data, and biology. We are thrilled to be joining forces with ...

AstraZeneca ties up with AI biologics company to develop cancer drug

AstraZeneca has signed a deal worth up to $247mn with Absci Corporation of the US to design an antibody to fight cancer.

Data Science & Artificial Intelligence - AstraZeneca

In 2021, we selected the first two AI-generated drug targets into our portfolio, from our collaboration with BenevolentAI. We share parts of our internal ...

AstraZeneca launches Evinova to bring AI to clinical trials

The new company will use established digital technology solutions to streamline clinical trial design and delivery in order to reduce time and costs in ...

Transforming AstraZeneca's R&D productivity

By adapting and redesigning our preclinical and early phase clinical trials, we are setting rigorous standards so we rapidly and efficiently select only the ...